Navigation Links
Apieron, Inc. Begins Customer Shipments of the Insight(TM) eNO System
Date:5/1/2008

Insight Measures Exhaled Nitric Oxide for More Targeted Asthma Control

MENLO PARK, Calif., May 1 /PRNewswire/ -- Apieron, Inc. (http://www.apieron.com) announced today that it has begun shipments of its Insight(TM) eNO System. Cleared by the FDA in March 2008, the Insight eNO System combines the accuracy, speed, and ease-of-use needed for the healthcare professional to provide office-based measurements of exhaled nitric oxide (eNO). Exhaled nitric oxide is a well established clinical indicator of airway inflammation and asthma control. With the use of eNO measurements, physicians can adjust inhaled corticosteroid therapy to optimize asthma control and avoid exacerbations or 'asthma attacks'.

The Insight eNO System's proprietary biosensor technology accurately measures eNO in parts per billion. Its single-use breath tubes are designed to be hygienic and convenient for the patient, and the disposable sensor generates a reading in less than a minute. Patient data can be stored and maintained in a unique format for trend analysis and printed for insurers' and patients' files. All of the System's functions are accessible through a small desktop monitor with a large color display and clinician-friendly interface.

"We showcased the Insight System at the March meeting of the American Academy of Allergy, Asthma and Immunology, and physicians responded enthusiastically to its graphical interface and its elegant technology," said Rich Lotti, President and CEO of Apieron, Inc. "As current methods for monitoring asthma airway inflammation are subjective, the Insight eNO System provides quantifiable information to increase therapeutic compliance. We believe this product will enable physicians to optimize medical therapy on an individualized basis, and therefore improve the standard of care for patients with asthma."

Sales and distribution of the Insight eNO System have been initiated with the int
'/>"/>

SOURCE Apieron, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital
2. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
3. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
4. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Laboratories, Inc. (NASDAQ: IDXX ) today reported ... 11% versus the prior year period to $390 million. ... of 2014 versus the prior year period was 9%, ... . Earnings per diluted share ("EPS") for the quarter ... year period to $1.10."In the second quarter, we continued ...
(Date:7/25/2014)... CHICAGO, Ill., July 25, 2014 NOT ... DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE ... LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ... ended June 30, 2014. "This was another ... earnings per share above our original guidance and announced plans ...
(Date:7/24/2014)... OVERLAND PARK, Kan. , July 24, 2014 ... licensing of two compounds that will be added ... agreement with Australian-based CIMTECH Pty Ltd, a biotechnology ... and PAR 122 have shown promise in bone ... a license to develop the compounds for the ...
Breaking Medicine Technology:IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33IDEXX Laboratories Announces Second Quarter Results 34AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3
... March 19, 2012 Novartis Pharmaceuticals Corporation today ... 75 mcg is now available in the US ... is indicated for the long-term maintenance bronchodilator treatment ... obstructive pulmonary disease (COPD), including chronic bronchitis and/or ...
... Incorporated (Nasdaq: ARAY ), the premier radiation ... 2012 Industry Excellence Award by Microsoft® as part of the ... be honored at Convergence 2012 , the premier Microsoft ... Texas. The 2012 Customer Excellence Awards, which are ...
Cached Medicine Technology:Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 2Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 3Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 4Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 5Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 6Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease 7Accuray Receives Microsoft Dynamics® Customer Excellence Award 2Accuray Receives Microsoft Dynamics® Customer Excellence Award 3Accuray Receives Microsoft Dynamics® Customer Excellence Award 4
(Date:7/26/2014)... According to the Metabolic Enhancement Training program ... bodybuilding program that helps men lose body fat and ... The program also instructs men how to melt fat ... reveals in its review that this program includes a ... get ripped and jacked at the same time. Vkool ...
(Date:7/26/2014)... July 26, 2014 As the ... the true vision of Xoçai is ... its exclusive and healthy chocolate products. One such ... of cacao, açaí berries and blueberries, an ingredient ... high-antioxidant blend is utilized in all of Xoçai ...
(Date:7/25/2014)... Ireland (PRWEB) July 26, 2014 ... quality legal help to people who have suffered ... the launch of both their new company, and ... article on the new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims ... law. The focus of the company is always ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 In recent years, ... and eager to reverse the symptoms associated with age-related testosterone ... media at large, a new case study from ... benefits of testosterone therapy using bioidentical hormones. , The ... father from Seattle who found himself beginning to feel the ...
(Date:7/25/2014)... A federal judge has denied defense ... Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ) selected as ... go before a jury on September 1, 2014, Bernstein ... 18th, U.S. District Judge Ed Kinkeade of the Northern ... may proceed to trial against Johnson & Johnson, the ...
Breaking Medicine News(10 mins):Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... available at www.urac.org/bestpractices WASHINGTON, Feb. 13 ... Practices in Health Care Consumer Empowerment and Protection Conference ... In addition to Ian Morrison,s opening keynote address ... for Value for All Americans , and Lee Woodruff,s ...
... Medical Inc. (NYSE: SMA ), a leading independent ... other medical markets, announced today that Brian S. Moore, President ... President and Chief Financial Officer, are scheduled to present at ... Nevada, Las Vegas on Tuesday, February 24, 2009 at ...
... 13 Micromet, Inc. (Nasdaq: MITI ), today announced that ... Annual Orange County Growth Stock Conference at the Ritz-Carlton Laguna Niguel on ... Annual Orange County Growth Stock Conference, Date: ... Pacific Time, Place: The Ritz-Carlton Laguna Niguel, ...
... Feb. 13 /PRNewswire-Asia/ -- The Hong Kong Sanatorium ... team had,successfully performed a large number of cases ... the application of computer-assisted,navigation system since its first ... hospital in Hong Kong which has acquired the ...
... "number sense" appear to be part of the shared ... language to explain abstractions that apparently takes human math ... an assistant professor of psychology and neuroscience at Duke ... monkeys think about numbers without using language. She,s looking ...
... SAVANNAH, Ga., Feb. 13 Founders Club will donate $5 ... the Mammography Fund at St. Joseph,s/Candler. "The Mammography Fund ... crucial in the fight against cancer," Jeff Andrews, CEO of ... be sold at Edwin Watts Golf stores and specialty golf ...
Cached Medicine News:Health News:URAC Announces Agenda for 2009 Best Practices in Health Care Consumer Empowerment and Protection Conference 2Health News:URAC Announces Agenda for 2009 Best Practices in Health Care Consumer Empowerment and Protection Conference 3Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 2Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 3Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 4Health News:Navigation System Significantly Improves the Surgical Accuracy of Total Knee Replacement for Arthritis Patients 2Health News:Navigation System Significantly Improves the Surgical Accuracy of Total Knee Replacement for Arthritis Patients 3Health News:Navigation System Significantly Improves the Surgical Accuracy of Total Knee Replacement for Arthritis Patients 4Health News:Pre-verbal number sense common to monkeys, babies, college kids 2Health News:Founders Club Proudly Supports the St. Joseph's/Candler Mammography Fund 2
ARION is a long-pulsed alexandrite laser system with a wavelength of 755 nm...
... to connect an infusion ... pump, and then to ... order to conduct urodynamics ... Laborie Medical Technologies infusion ...
Used for suprapubic monitoring of bladder pressures. Suprapubic urodynamic studies avoid the effects of urethral catheterization and eliminate the need for a double bladder puncture. Supplied sterile...
... Triage® Cardiac Panel is a ... rapid quantitative determination of CK-MB, ... ethylenediaminetetraacetic acid (EDTA) whole blood ... is used as an aid ...
Medicine Products: